GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings Corp. faces a securities class action lawsuit for failing to disclose material information about its acquisition performance. The company reported a significant drop in adjusted gross margin (74% to 69%), missed revenue estimates, lowered full-year guidance from $540-$550M to $475-$490M, and disclosed a $31.2M impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% on May 4, 2026. Investors who purchased shares between April 16, 2025 and May 4, 2026 have until August 3, 2026 to file lead plaintiff applications.